Key facts
- This page summarizes Andrew C. Orth's Form 4 filing for Krystal Biotech, Inc. (KRYS).
- 5 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 09 Jun 2023, 19:00.
Andrew C. Orth - 09 Jun 2023 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- KRYS
- Reported as of
- 09 Jun 2023
- Net transaction value
- -$813,260
- SEC form
- 4
- Accepted by SEC
- 09 Jun 2023, 19:00:15 UTC
- Prior SEC filing
- 28 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrew Orth
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Andrew C. Orth filed Form 4 for Krystal Biotech, Inc. (KRYS) on 09 Jun 2023.
Change
- Previous filing in this sequence was filed on 28 Feb 2023.
- Current net transaction value: -$813,260.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KRYS
transaction
Common Stock
Options Exercise
- Transaction value
- $794,375
- Shares
- +12,500
- Change %
- +12500%
- Price
- $63.55
- Shares after
- 12,600
- Date
- 09 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
KRYS
transaction
Common Stock
Sale
- Transaction value
- $673,958
- Shares
- -5,261
- Change %
- -42%
- Price
- $128.10
- Shares after
- 7,339
- Date
- 09 Jun 2023
- Ownership
- Direct
- Footnotes
- F1, F2
KRYS
transaction
Common Stock
Sale
- Transaction value
- $890,488
- Shares
- -6,906
- Change %
- -94%
- Price
- $128.94
- Shares after
- 433
- Date
- 09 Jun 2023
- Ownership
- Direct
- Footnotes
- F1, F3
KRYS
transaction
Common Stock
Sale
- Transaction value
- $43,189
- Shares
- -333
- Change %
- -77%
- Price
- $129.70
- Shares after
- 100
- Date
- 09 Jun 2023
- Ownership
- Direct
- Footnotes
- F1, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KRYS
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -12,500
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 37,500
- Date
- 09 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,500
- Exercise price
- $63.55
- Footnotes
- F1, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 5 footnotes
Footnote F1
The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on March 10, 2023 and will terminate on March 31, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $113.00 per share.
Footnote F2
The transaction was executed in multiple trades ranging from $127.5500 to $128.5400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F3
The transaction was executed in multiple trades ranging from $128.5600 to $129.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F4
The transaction was executed in multiple trades ranging from $129.5600 to $129.7400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
Footnote F5
50,000 options were granted that vest in four equal annual installments beginning on February 28, 2023.